Outlook Therapeutics (OTLK) Other Non-Current Liabilities (2015 - 2026)
Outlook Therapeutics (OTLK) reported Other Non-Current Liabilities of $722229.0 for Q1 2026, down 86.75% year-over-year from $5.5 million in Q1 2025, and down 90.45% quarter-over-quarter from $7.6 million in Q4 2025.
Outlook Therapeutics (OTLK) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Other Non-Current Liabilities data on file, last reported at $722229.0 in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $722229.0, down 86.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $722229.0 (down 86.75% YoY), and the FY2025 annual result was $4.8 million, down 91.93% from the prior year.
- Other Non-Current Liabilities fell to $722229.0 in Q1 2026 per OTLK's latest filing, from $7.6 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $139.2 million in Q1 2024 and troughed at $6219.0 in Q3 2023.
- A 5-year average of $19.5 million and a median of $722229.0 in 2026 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities sank 97.23% in 2023, then soared 1684331.11% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $26878.0 in 2022, then soared by 121.6% to $59561.0 in 2023, then soared by 31508.15% to $18.8 million in 2024, then plunged by 59.84% to $7.6 million in 2025, then sank by 90.45% to $722229.0 in 2026.
- Business Quant data shows OTLK's Other Non-Current Liabilities at $722229.0 in Q1 2026, $7.6 million in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 722,229.00 |
| Dec 31, 2025 | 7.56 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 7.45 Mn |
| Mar 31, 2025 | 5.45 Mn |
| Dec 31, 2024 | 18.83 Mn |
| Sep 30, 2024 | 59.10 Mn |
| Jun 30, 2024 | 87.95 Mn |
| Mar 31, 2024 | 139.18 Mn |
| Dec 31, 2023 | 59,561.00 |
| Sep 30, 2023 | 6,219.00 |
| Jun 30, 2023 | 20,012.00 |
| Mar 31, 2023 | 8,263.00 |
| Dec 31, 2022 | 26,878.00 |
| Sep 30, 2022 | 57,138.00 |
| Jun 30, 2022 | 68,319.00 |
| Mar 31, 2022 | 298,033.00 |
| Dec 31, 2021 | 273,020.00 |
| Sep 30, 2021 | 522,918.00 |
| Jun 30, 2021 | 434,248.00 |